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Aim: To estimate and compare the results from all randomized trials of triple combinations of 
anti-diabetes therapies that reported the reduction of glycated haemoglobin (HbA1c) and 
associated effects on body weight and hypoglycaemia. 
Methods: PubMed and the Cochrane Library were searched for trials with at least one study 
arm on triple therapy and which reported the differences in mean change in HbA1c between 
two study arms. These were included in a network meta-analysis. 
Results: Altogether, 15182 participants from 40 trials with treatment duration of 6 to 12 months 
were included. Compared with none/placebo added to dual therapy, the addition of a drug 
therapy from six of eight drug classes to existing dual therapy resulted in significant additional 
mean reductions in HbA1c from -0.56% (-6.2 mmol/mol; dipeptidyl peptidase 4 inhibitors) to -
0.94% (-10.3 mmol/mol; thiazolidinediones). Of the six drug classes, three were associated with 
less favourable weight change and two were associated with more favourable weight change 
when compared with none/placebo added to dual therapy. Furthermore, five drug classes were 
associated with greater odds of hypoglycaemia.  Similar results were observed in analyses of 
studies with 6 months treatment duration and after excluding study arms that contained insulin. 
Conclusions: Overall triple therapy combinations were similar in improving diabetes control 
although there were some differences in adverse effects. By balancing the risks and benefits of 
each therapy, the estimates of pairwise comparisons of triple therapies for HbA1c, body weight 
and hypoglycaemia provided in this study may further inform evidence based practice. 
 





In clinical practice, glucose-lowering pharmacotherapy is prescribed when lifestyle modification 
is not effective in the management of type 2 diabetes. If glycaemic control becomes inadequate 
with a single therapy, a second and then a third therapy may be added to the treatment, while 
reinforcing the importance of lifestyle modification [1]. A network meta-analysis published in 
2011 compared the effects of a number of therapies added to metformin (MET) and 
sulfonylurea (SU) for the treatment of type 2 diabetes [2]. However, triple therapy combinations 
other than those that include both MET and SU are increasingly used and may result in greater 
reduction in glycated haemoglobin (HbA1c). A randomised trial that compared the triple 
combinations MET/SU/DPP-4 (dipeptidyl peptidase 4 inhibitors) and MET/DPP-4/INS (insulin) 
reported a -0.40% [95% confidence intervals: -0.66, -0.15] (-4.4 [-7.3, -1.7] mmol/mol) greater 
reduction in HbA1c with MET/DPP-4/INS after a six month treatment period [3].  Moreover, a 
third therapy is usually added to the existing dual therapy treatment and because of 
individualized treatment plans, patients may not necessarily be taking the MET/SU dual therapy 
combination.  Therefore, we aimed to estimate and compare the effect of all triple therapy 
combinations that have been studied in clinical trials on glycaemic control as assessed by HbA1c 
and to examine the effect on weight changes and hypoglycaemia to further inform evidence 
based practice in the management of type 2 diabetes. 
 
Materials and methods 
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We consulted the PRISMA extension statement for reporting of systematic reviews 
incorporating network meta-analyses checklist in preparation of this review [4]. 
 
Literature search 
We searched PubMed and the Cochrane Library for relevant studies that were published to 8th 
April 2015, using a combination of key words and MeSH terms: “biguanides”, “metformin”, 
“sulfonamides”, “sulfonylureas”, “glibenclamide”, “gliclazide”, “glimepiride”, “glipizide”, 
“glyburide”, “dipeptidyl peptidase 4 inhibitors”, “DPP-4 inhibitors”, “gliptins”, “alogliptin”, 
“linagliptin”, “saxagliptin”, “sitagliptin”, “vildagliptin”, “GLP-1 receptor agonists”, “incretin 
analogues”, “albiglutide”, “exenatide”, “liraglutide”, “lixisenatide”, “sodium glucose co-
transporter inhibitors”, “SGLT2 inhibitors”, “canagliflozin”, “dapagliflozin”, “empagliflozin”, 
“alpha glucosidase inhibitors”, “acarbose”, “miglitol”, “voglibose”, “thiazolidinediones”, “TZD”, 
“glitazones”, “pioglitazone”, “rosiglitazone”, “insulin”, “meglitinide”, “nateglinide”, 
“repaglinide”, “type 2 diabetes”, and “clinical trial”. The full electronic search strategy is 
provided in Appendix. References from relevant studies and reviews were inspected to identify 
other potential studies. No language restriction was applied. 
 
Study selection, data extraction, and quality assessment 
Studies were included if they fulfilled the following criteria: randomised trials in adults (aged ≥ 
18 years) with type 2 diabetes; at least one study arm involved triple therapy; at least two study 
arms were on different drug class combinations; and reported the mean change and its 
variability (i.e. standard deviation, standard error, or 95% confidence interval) in HbA1c from 
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baseline for each study arm or the difference in mean change and its variability between two 
study arms. Attempts were made to include studies that did not report the required summary 
statistics on HbA1c by contacting the corresponding authors of these studies. Drug classes 
available for the treatment of type 2 diabetes include MET, SU, DPP-4, INS, glucagon-like 
peptide-1 receptor agonist (GLP-1), sodium-glucose linked transporter protein 2 inhibitors 
(SGLT2), alpha glucosidase inhibitors (AGI), thiazolidinediones (TZD), and meglitinides (MEG). 
 
Studies were excluded if the treatment period was less than 20 weeks, since adjustments to 
dosages, such as for INS, may take place in the first few weeks of the treatment period and 
change in HbA1c may not be noticeable in the first three months due to the 120 day life span of 
red blood cells. Studies with treatment duration greater than 54 weeks that did not report 
interim results during the first 6 to 12 months of treatment, sample size less than 30 per study 
arm, or compared a triple therapy arm with a monotherapy arm were also excluded. Studies 
that combined participants on different background therapy combinations during the treatment 
period were excluded unless mean changes in HbA1c were reported for the subgroups that 
were on the same background therapy combinations.  
 
Literature search and data extraction were conducted by C.M.Y.L in consultation with S.C. 
Information extracted from each study included study characteristics (name of primary author, 
year of publication, location of trial, drug class combinations, sample size and details of 
medications used for each study arm, treatment duration, and analysis set used), baseline 
characteristics of studied populations (proportion of females, mean age, mean body mass index, 
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mean duration of diabetes, and mean HbA1c), and study outcomes (change in HbA1c, change in 
body weight, and number of participants experienced at least mild hypoglycaemia during 
treatment period). For studies that have multiple follow-up visits, data collected closest to 6 
months after the start of treatment were included in the analysis. For multi-arm studies that 
included study arms that were assigned the same drug class combinations but at different 
dosages for one of the drugs, the study arm allocated the dosage that was most commonly used 
in other studies for that drug was included in the analysis. The Jadad Scale was used to assess 
the quality of the included studies [5]. 
 
Data analysis 
We estimated the mean difference in HbA1c between each drug class added to an existing dual 
therapy compared to adding a nothing or adding a placebo (none/placebo) to an existing dual 
therapy to determine if any of the third therapy added to existing dual therapy is superior in 
reducing HbA1c.. Since not all triple therapies have been compared in randomised trials, a 
multivariate network meta-analysis was employed instead of a traditional pairwise meta-
analysis. Multivariate network meta-analysis can provide estimates for all pairwise comparisons 
that are linked to a network of trials through utilising both direct evidence obtained from 
studies directly comparing drug class combinations and indirect evidence estimated through a 
common comparator [6]. Furthermore, information from multi-arm studies can be included in 
the network meta-analysis, thus increasing the number of studies that can be included in the 
analysis. Estimates of all pairwise comparisons of triple therapies were provided to assist in the 
selection of the drug class that appears most appropriate as add on to existing dual therapy. In 
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order to assess the adverse effects of the triple therapy combinations, the analyses were 
repeated for difference in mean change in body weight reported as kilograms and for difference 
in the proportion of participants who experienced hypoglycaemia reported as odds ratios. Since 
the level of HbA1c may be different at 6 months and 12 months after the start of treatment, a 
sensitivity analysis was conducted restricted to studies with about 6 months (20-30 weeks) 
treatment duration. Analyses were also repeated after excluding study arms that contained 
insulin, and after removing studies that were rated “poor” based on the Jadad Scale. 
 
Multiple-outcomes meta-analysis was conducted using network, a suite of Stata commands for 
network meta-analysis within a frequentist framework [7]. A network plot was used to assess 
the geometry of the network [4]. Each node represents a drug class added to existing dual 
therapy and direct comparisons between drug classes are represented by connections between 
the nodes. The number of studies available per direct comparison is provided in the network. 
The size of the node reflects the number of studies available for the drug class. Estimates 
derived from consistency models are reported. Overall  inconsistency across comparisons 
between direct and indirect evidence were tested using the design-by-treatment interaction 
inconsistency model. Relative rankings of the therapy combinations were estimated using the 
surface under the cumulative ranking curve (SUCRA). SURCA is the cumulative probabilities of a 
treatment to achieve each of all possible ranks out of all competing treatments [8]. For instance, 
if three treatments were compared, SUCRA for treatment 1 would be the cumulative 
probabilities of treatment 1 ranking first out of all three treatments, ranking second out of all 
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three treatments, and ranking third out of all three treatments. All statistical analyses were 
performed using Stata/IC 12.0 for Windows (Stata Corp LP., College Station, TX, USA).  
 
Results 
A total of 11666 titles and abstracts were screened after duplicates were removed 
(Supplementary Figure 1). Of these, 137 articles were retrieved to assess their eligibility and 87 
articles were removed based on our inclusion and exclusion criteria. Nine authors were 
contacted for missing data; three authors provided additional information and missing data 
from two studies were obtained from a published meta-analysis. A further six articles were 
removed; four trials had sample size less than 30 per arm and two trials were included in other 
publications. Therefore, 40 studies were included in the network meta-analysis. 
 
Characteristics of included studies 
Altogether, 15182 participants with type 2 diabetes from 40 trials with treatment duration 
ranging from 20 to 54 weeks (90% of trials with treatment duration of 6 months (20-30 weeks)) 
were available for analysis (Table 1). The characteristics of the studied populations varied with 
baseline mean values ranging from 52.6 to 65.3 years (median 56.6 years) for age, 7.2 to 10.2% 
(55 to 88 mmol/mol) (median 8.3% (67 mmol/mol)) for HbA1c, 26.2 to 34.4 kg/m2 (median 31.2 
kg/m2) for body mass index, and 4.7 to 13.0 years (median 9.0 years) for duration of diabetes. 
Analyses were conducted on the full analysis set or intention-to-treat in 36 studies, per protocol 
in 3 studies, and not reported in 1 study. Details of medications used in each study are provided 
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in supplementary table 1. Of the 33 studies with a dual therapy arm, 27 included a placebo. The 
quality of studies was rated “good” in 93% of the trials (Supplementary table 2). 
 
HbA1c 
A network plot of diabetes treatment combinations for all trials which reported HbA1c and had 
a treatment duration of 6 to 12 months (20-54 weeks) is presented in Figure 1. Four of the 40 
trials included had three arms but two of the trials had two dual therapy arms, hence,  46 direct 
comparisons were available for comparison among nine therapy combinations (one dual 
(none/placebo added) and eight triple). Where available, the number of studies per direct 
comparison between therapy combination pairs ranged from 1 to 13. The triple therapies 
available for comparison comprised SU, DPP-4, GLP-1, SGLT2, INS, AGI, TZD or MEG added to 
existing dual therapy. 
 
Compared with none/placebo added to dual therapy, the addition of a third therapy to existing 
dual therapy resulted in significant additional mean reductions in HbA1c, which ranged from -
0.56% [95% confidence intervals: -0.70, -0.42] (-6.2 mmol/mol [-7.7, -4.6]) for DPP-4 to -0.94% [-
1.18, -0.70] (-10.3 mmol/mol [-13.0, -7.7]) for TZD (Figure 2). Non-significant mean reductions in 
HbA1c were observed when AGI or MEG was added to dual therapy. When a third therapy was 
compared with other third therapies added to existing dual therapy, significant difference was 
observed between DPP-4 and GLP-1, INS, and TZD (Supplementary table 3). TZD was ranked the 
most effective in the reduction of HbA1c (SUCRA = 89.6%). There was limited evidence to 
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suggest inconsistency between studies (p = 0.80). Estimates of all pairwise comparisons of triple 
therapies for HbA1c are provided in Supplementary table 3.  
 
When study arms containing insulin were excluded, 28 studies with 31 direct comparisons were 
available for seven therapy combinations (MEG was not studied in these trials). TZD remained 
the most effective in the reduction of HbA1c (SUCRA = 89.2%). Of note, however, the point 
estimate of the mean reduction in HbA1c for SU was 0.4% (4.4 mmol/mol) greater than in the 
analysis of all studies (from -0.59% [-0.90, -0.28] (6.5 mmol/mol [-9.9, 3.1]) to -0.99% [-1.32, -
0.66] (-10.9 [-14.5, -7.3])) and its relative ranking improved with SUCRA value increasing from 
43.8% to 87.1%. 
 
In the 34 studies with around 6 months treatment duration, 38 direct comparisons were 
available for nine therapy combinations. The overall conclusion did not differ when compared 
with the 6 to 12 months results. Removal of three studies that were rated “poor” also did not 




Body weight was reported in 27 two-arm studies and 4 three-arm studies (2 with two dual 
therapy arms), which resulted in 37 direct comparisons available for eight therapy combinations 
(data were not available for AGI). Compared with none/placebo added to dual therapy, a more 
favourable weight difference was observed for GLP-1 (-1.85 kg [-2.81, -0.89]) and SGLT-2 (-1.79 
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kg [-3.03, -0.55]) (Figure 3). There was, however, evidence of inconsistency between direct and 
indirect evidence (p < 0.0001). According to the SUCRA values for body weight and HbA1c, the 
two drug classes (TZD, INS) that ranked highest for their effectiveness in the reduction of HbA1c 
ranked poorly for body weight due to their effect on weight gain (Figure 4). GLP-1 (73.7% and 
91.9%) and SGLT-2 (57.3% and 90.6%) have relatively high SUCRA values for both HbA1c and 
body weight. Estimates of all pairwise comparisons of triple therapies for body weight are 
provided in Supplementary table 4. Network meta-regression was not performed to investigate 
whether baseline mean weight was a possible explanation for inconsistency due to the limited 
studies available for each comparison. However, there was no systematic ordering (higher to 
lower) of baseline mean weight weighted by sample size according to the order of mean 
difference in body weight (weight reduction to weight gain) between triple therapy 
combinations when compared with none/placebo added to dual therapy. 
 
Similar results were obtained when study arms containing insulin were removed from analysis. 
For sensitivity analysis of studies with about 6 months treatment duration, similar results were 
observed except that the mean difference in body weight became non-significant for SU (0.90 
kg [-0.40, 2.20]) and there was limited evidence to suggest inconsistency (p = 0.53). 
 
Hypoglycaemia 
Twenty-seven studies reported the number of participants that experienced at least one 
episode of mild, or worse, hypoglycaemia during the treatment period, which resulted in 33 
direct comparisons available for nine therapy combinations. Estimates of all pairwise 
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comparisons of triple therapies for hypoglycaemia are provided in Supplementary table 5. 
Compared with none/placebo added to dual therapy, the odds of hypoglycaemia were higher 
for DPP-4 (1.95 [1.15, 3.29]), SGLT2 (2.27 [1.07, 4.82]), GLP-1 (2.61 [1.42, 4.79]), TZD (2.83 [1.22, 
6.57]), and INS (5.94 [2.80, 12.60]). There was limited evidence of inconsistency between 
studies (p = 0.61).  
 
When study arms containing insulin were removed from analysis, the odds of hypoglycaemia 
also became significantly higher for SU (11.54 [4.75, 27.99]). For studies with about six months 
treatment duration, only GLP-1 (2.46 [1.24, 4.88]) and INS (3.80 [1.62, 8.89]) were associated 
with greater odds of hypoglycaemia than none/placebo added to dual therapy. 
 
Discussion 
This is the first study which estimated and compared the effectiveness of all triple therapy 
combinations that have been studied in randomised trials, not limited to those that included 
both MET and SU [2], on HbA1c and the associated effect on body weight and hypoglycaemia. 
There is general consensus that additional reduction in HbA1c can be achieved by adding a third 
therapy to existing dual therapy treatment. Gross et al reported a 0.70% (7.7 mmol/mol; 
acarbose) to 1.08% (11.9 mmol/mol; INS) additional absolute HbA1c reduction with a third 
therapy added to MET/SU compared with MET/SU [2] and in the present study we found an 
additional 0.56% (6.2 mmol/mol; DPP-4) to 0.94% (10.3 mmol/mol; TZD) HbA1c reduction for a 
third therapy added to an existing dual therapy. This reduction in HbA1c is clinically relevant. 
The UK Prospective Diabetes Study reported a 37% reduction in the risk of microvascular 
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complications and 14% reduction in the risk of myocardial infarction for each 1% (11 mmol/mol) 
reduction in HbA1c [48]. For a difference of 0.8% (9 mmol/mol) in HbA1c, the Action in Diabetes 
and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial reported a 14% reduction in the risk of major microvascular events [49]. A 
meta-analysis on the effects of glucose lowering and cardiovascular disease, which included 
ADVANCE, found that a difference of 0.88% (9.7 mmol/mol) in HbA1c was associated with a 9% 
reduction in the risk of a major cardiovascular event [50].  
 
The specific question addressed by our study was whether there were clinically relevant 
differences between the various currently available triple therapy combinations. We found no 
statistical difference in the reduction of HbA1c between six of the drug classes added as a third 
therapy to existing dual therapy when compared with dual therapy. However, differences were 
observed between DPP-4 and GLP-1, INS, and TZD when triple therapies were compared. 
 
These changes in HbA1c should be considered in the context of other clinically relevant effects. 
Estimates of all pairwise comparisons of triple therapies for HbA1c, body weight and 
hypoglycaemia provided in Supplementary tables 3 to 5 can potentially be used to assist in the 
selection of drug class as add on to existing dual therapy. For example, compared with DPP-4 (a 
common first choice added to existing dual therapy), GLP-1 is associated with a 0.25% (2.8 
mmol/mol) significantly greater absolute reduction in HbA1c and a 1.9 kg significantly more 
favourable weight change. In contrast, compared with DPP-4, INS is associated with a 0.35% (3.9 
mmol/mol) significantly greater reduction in HbA1c but also a significant 2.3 kg weight gain. 
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Furthermore, there are also clinically relevant differences in risk of hypoglycaemia between the 
various therapeutic agents [1,51]. 
 
The major strength of this study was that we have compared the relative effects of nine drug 
classes as add-ons to existing dual therapy on the reduction of HbA1c. However, we were 
unable to conduct in depth analyses of potential confounders due to the limited number of 
studies available for each pairwise comparison. For instance, the differences in baseline mean 
age, body mass index, body weight, HbA1c and duration of diabetes among the 40 trials may 
have influenced the estimates but we were unable to conduct network meta-regression to 
explore the effects that these differences may have had on our results. Nevertheless, the 
baseline mean HbA1c weighted by sample size were similar between drug classes, which ranged 
from 8.3% (67 mmol/mol) to 8.5% (69 mmol/mol) except for MEG (7.5% (59 mmol/mol)), SGLT2 
(8.1% (65 mmol/mol)) and AGI (8.8% (73 mmol/mol)). The lack of direct evidence between drug 
classes also meant that most comparisons were estimated through direct evidence from one or 
two studies and indirect evidence. We tested for the overall inconsistency in the network using 
a global method, yet we were unable to test loop specific inconsistency since most pairwise 
comparisons only have one study [52]. Furthermore, we have combined study arms that had the 
same drug class combinations but the drugs used within the same drug class differed among 
studies, although differences between drugs within the same class are mostly related to adverse 
effects, rather than in their efficacy in reducing HbA1c. Therefore, it is clinically plausible to 
combine studies that used different drugs within the same drug class. We have also combined 
all existing dual therapy combinations since, in clinical practice, a third therapy is only added 
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when existing dual therapy is no longer effective in controlling blood glucose. The effect of a 
drug class such as DPP-4 added to any existing dual therapy combinations should result in 
similar mean difference in HbA1c. We were unable to estimate the odds of severe 
hypoglycaemia associated with these triple therapy combinations as few studies reported these 
severe events. Moreover, hypoglycaemia data were the least robust as non-standardised 
definitions and grading were used. 
 
Clinically relevant additional reduction in HbA1c can be achieved with triple therapy. As 
described above, the estimates provided in this study may be used to guide clinical practice 
since it is unlikely that a randomised trial will compare all triple therapy combinations included 
here. Nevertheless, readers should be aware of the limitations in this study and treat these 
estimates as a general guide rather than precise evidence. 
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Figure 1: Network plot of available diabetes treatment combinations for studies with a 
treatment duration of 6 to 12 months (20-54 weeks) 
The number of studies available per direct comparison is provided in the network. The size of 




Figure 2: Mean difference in HbA1c (%)* of drug classes added to existing dual therapy 
compared with placebo/none added to dual therapy for studies with a treatment duration of 6 
to 12 months (20-54 weeks) 




Figure 3: Mean difference in body weight (kg) of drug classes added to existing dual therapy 
compared with placebo/none added to dual therapy for studies with a treatment duration of 6 




Figure 4: Surface under the cumulative ranking curve (SUCRA) values of HbA1c by body weight 
for all triple therapies with data for HbA1c and body weight for studies with a treatment 
duration of 6 to 12 months (20-54 weeks) 
Higher SUCRA values for HbA1c indicate greater effectiveness in the reduction of HbA1c. 





Table 1: Characteristics of included studies 
Study Country Study arms 
included in analysis 
(Combinations by 
drug class) 






Baseline mean Analysis 
set used 













24 weeks 47 8.5 61.5 8.8 
(73) 
27.8 PP 




24 weeks 44 11.4 59.0 9.6 
(81) 
30.1 FAS/ITT 
















30 weeks 42 9.1 55.5 8.5 
(69) 
34 FAS/ITT 






26 weeks 38 8.3 56.5 8.2 
(66) 
33.4 FAS/ITT 






24 weeks 48 8.3 55.6 8.7 
(72) 
34.1 FAS/ITT 








(52% of entire cohort) 
24 weeks 48 9.9 57.1 8.3 
(67) 
31.0 FAS/ITT 
















26 weeks 57 8.0 65.3 8.1 
(65) 
29.7 - 








24 weeks 52 9.0 52.6 10.2 
(88) 
33.8 FAS/ITT 






24 weeks 45 9.4 56.0 7.4 
(57) 
32.8 FAS/ITT 




34 weeks 58 8.8 53.8 8.1 
(65) 
32.9 FAS/ITT 















26 weeks 44 9 55 8.5 
(69) 
33.7 FAS/ITT 








20 weeks 49 4.7 56 7.8 
(62) 
32.5 FAS/ITT 








(95% of entire cohort) 
26 weeks 41 6.3 54.7 8.2 
(66) 
33.7 FAS/ITT 






(72% of entire cohort) 
24 weeks 49 12.5 57.7 8.6 
(71) 
31 FAS/ITT 






52 weeks (interim 
data for 26 weeks) 
48 7.2 55.1 8.2 
(66) 
31.5 PP 








(76% of entire cohort) 
26 weeks 46 9.8 56.9 8.5 
(69) 
31.9 FAS/ITT 

















(69% of entire cohort) 
24 weeks 59 11.9 57.2 8.7 
(72) 
32.3 FAS/ITT 








(75% of entire cohort) 
26 weeks 56 6.4 54.5 8.5 
(69) 
31.2 FAS/ITT 






26 weeks 45 8.6 57.0 7.6 
(60) 
34.4 FAS/ITT 








20 weeks 50 8 56 7.9 
(63) 
31.2 PP 






52 weeks 50 - - 7.2 
(55) 
27.5 FAS/ITT 








54 weeks 43 9.3 54.5 8.8 
(73) 
30.3 FAS/ITT 




[34] countries MET/TZD  n2= 156 (73) 

















(62% of entire cohort) 
24 weeks 50 13.0 59.2 8.8 
(73) 
28.9 FAS/ITT 




24 weeks 63 7.8 59.1 8.4 
(68) 
26.2 FAS/ITT 








52 weeks 44 9.6 56.7 8.1 
(65) 
31.6 FAS/ITT 








52 weeks (interim 
data for 26 weeks) 
50 9.9 56.5 8.1 
(65) 
33.0 FAS/ITT 








(74% of entire cohort) 













(51% of entire cohort) 
24 weeks 41 6.6 56.7 7.9 
(63) 
- FAS/ITT 







(75% of entire cohort) 













24 weeks 52 7.3 55.1 8.8 
(73) 
28.0 FAS/ITT 






24 weeks 40 - 57.0 8.3 
(67) 
29.3 FAS/ITT 








52 weeks (Placebo 
only included in 
first 26 weeks) 
43 9 55 8.1 
(65) 
33.7 FAS/ITT 








52 weeks 47 8.9 55.2 8.2 
(66) 
32.2 FAS/ITT 














AGI=alpha glucosidase inhibitor; BMI=body mass index; DPP-4=dipeptidyl peptidase 4 inhibitor; FAS/ITT=full analysis set or intention-to-treat; FBG=fasting 
blood glucose; FPG=fasting plasma glucose; GLP-1=Glucagon-like peptide-1 receptor agonist; HbA1c=glycated haemoglobin; INS=insulin; MEG=meglitinide; 




Full electronic search strategy for PubMed 
(("biguanides"[MeSH Terms] OR "biguanides"[All Fields]) OR ("metformin"[MeSH Terms] OR 
"metformin"[All Fields]) OR ("sulphonamides"[All Fields] OR "sulfonamides"[MeSH Terms] OR 
"sulfonamides"[All Fields]) OR ("sulfonylurea compounds"[MeSH Terms] OR ("sulfonylurea"[All 
Fields] AND "compounds"[All Fields]) OR "sulfonylurea compounds"[All Fields] OR "sulfonylureas"[All 
Fields]) OR ("glyburide"[MeSH Terms] OR "glyburide"[All Fields] OR "glibenclamide"[All Fields]) OR 
("glyburide"[MeSH Terms] OR "glyburide"[All Fields]) OR ("gliclazide"[MeSH Terms] OR 
"gliclazide"[All Fields]) OR ("glimepiride"[Supplementary Concept] OR "glimepiride"[All Fields]) OR 
("glipizide"[MeSH Terms] OR "glipizide"[All Fields]) OR ("glycoside hydrolase 
inhibitors"[Pharmacological Action] OR "glycoside hydrolase inhibitors"[MeSH Terms] OR 
("glycoside"[All Fields] AND "hydrolase"[All Fields] AND "inhibitors"[All Fields]) OR "glycoside 
hydrolase inhibitors"[All Fields] OR ("alpha"[All Fields] AND "glucosidase"[All Fields] AND 
"inhibitors"[All Fields]) OR "alpha glucosidase inhibitors"[All Fields]) OR ("acarbose"[MeSH Terms] OR 
"acarbose"[All Fields]) OR ("voglibose"[Supplementary Concept] OR "voglibose"[All Fields]) OR 
("miglitol"[Supplementary Concept] OR "miglitol"[All Fields]) OR ("thiazolidinediones"[MeSH Terms] 
OR "thiazolidinediones"[All Fields]) OR TZD[All Fields] OR ("thiazolidinediones"[MeSH Terms] OR 
"thiazolidinediones"[All Fields] OR "glitazones"[All Fields]) OR ("pioglitazone"[Supplementary 
Concept] OR "pioglitazone"[All Fields]) OR ("rosiglitazone"[Supplementary Concept] OR 
"rosiglitazone"[All Fields]) OR ("dipeptidyl-peptidase iv inhibitors"[Pharmacological Action] OR 
"dipeptidyl-peptidase iv inhibitors"[MeSH Terms] OR ("dipeptidyl-peptidase"[All Fields] AND "iv"[All 
Fields] AND "inhibitors"[All Fields]) OR "dipeptidyl-peptidase iv inhibitors"[All Fields] OR "dipeptidyl 
peptidase 4 inhibitors"[All Fields]) OR (dpp-4[All Fields] AND ("antagonists and 
inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists 
and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR ("dipeptidyl-peptidase iv 
inhibitors"[Pharmacological Action] OR "dipeptidyl-peptidase iv inhibitors"[MeSH Terms] OR 
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("dipeptidyl-peptidase"[All Fields] AND "iv"[All Fields] AND "inhibitors"[All Fields]) OR "dipeptidyl-
peptidase iv inhibitors"[All Fields] OR "gliptins"[All Fields]) OR ("alogliptin"[Supplementary Concept] 
OR "alogliptin"[All Fields]) OR ("Linagliptin"[Supplementary Concept] OR "Linagliptin"[All Fields] OR 
"linagliptin"[All Fields]) OR ("saxagliptin"[Supplementary Concept] OR "saxagliptin"[All Fields]) OR 
("sitagliptin"[Supplementary Concept] OR "sitagliptin"[All Fields]) OR ("vildagliptin"[Supplementary 
Concept] OR "vildagliptin"[All Fields]) OR (("sodium, dietary"[MeSH Terms] OR ("sodium"[All Fields] 
AND "dietary"[All Fields]) OR "dietary sodium"[All Fields] OR "sodium"[All Fields] OR "sodium"[MeSH 
Terms]) AND ("glucose"[MeSH Terms] OR "glucose"[All Fields]) AND co-transporter[All Fields] AND 
("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) 
OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR (sglt2[All Fields] AND 
("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) 
OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR 
("canagliflozin"[Supplementary Concept] OR "canagliflozin"[All Fields]) OR ("2-(3-(4-ethoxybenzyl)-4-
chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"[Supplementary Concept] OR "2-(3-
(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"[All Fields] OR 
"dapagliflozin"[All Fields]) OR ("empagliflozin"[Supplementary Concept] OR "empagliflozin"[All 
Fields]) OR (("glucagon-like peptide-1 receptor"[Supplementary Concept] OR "glucagon-like peptide-
1 receptor"[All Fields] OR "glp 1 receptor"[All Fields]) AND ("agonists"[Subheading] OR "agonists"[All 
Fields])) OR (("incretins"[Pharmacological Action] OR "incretins"[MeSH Terms] OR "incretins"[All 
Fields] OR "incretin"[All Fields]) AND analogues[All Fields]) OR ("exenatide"[Supplementary Concept] 
OR "exenatide"[All Fields]) OR ("liraglutide"[Supplementary Concept] OR "liraglutide"[All Fields]) OR 
("rGLP-1 protein"[Supplementary Concept] OR "rGLP-1 protein"[All Fields] OR "albiglutide"[All 
Fields]) OR ("ZP10A peptide"[Supplementary Concept] OR "ZP10A peptide"[All Fields] OR 
"lixisenatide"[All Fields]) OR ("insulin"[MeSH Terms] OR "insulin"[All Fields]) OR 
("meglitinide"[Supplementary Concept] OR "meglitinide"[All Fields]) OR 
("nateglinide"[Supplementary Concept] OR "nateglinide"[All Fields]) OR 
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("repaglinide"[Supplementary Concept] OR "repaglinide"[All Fields])) AND ("diabetes mellitus, type 
2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "type 2 diabetes"[All Fields]) AND 
("clinical trial"[Publication Type] OR "clinical trials as topic"[MeSH Terms] OR "clinical trial"[All 
Fields]) 
 
Full electronic search strategy for the Cochrane Library 
'((biguanides) OR (metformin) OR (sulfonamides) OR (sulfonylureas) OR (glibenclamide) OR 
(glyburide) OR (gliclazide) OR (glimepiride) OR (glipizide) OR (alpha glucosidase inhibitors) OR 
(acarbose) OR (voglibose) OR (miglitol) OR (thiazolidinediones) OR (TZD) OR (glitazones) OR 
(pioglitazone) OR (rosiglitazone) OR (dipeptidyl peptidase 4 inhibitors) OR (dpp-4 inhibitors) 
OR (gliptins) OR (alogliptin) OR (linagliptin) OR (saxagliptin) OR (sitagliptin) OR (vildagliptin) 
OR (sodium glucose co-transporter inhibitors) OR (sglt2 inhibitors) OR (canagliflozin) OR 
(dapagliflozin) OR (empagliflozin) OR (glp-1 receptor agonists) OR (incretin analogues) OR 
(exenatide) OR (liraglutide) OR (albiglutide) OR (lixisenatide) OR (insulin) OR (meglitinide) OR 
(nateglinide) OR (repaglinide)) AND (type 2 diabetes) AND (clinical trial) in Trials' 
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Supplementary table 1: Description of medications used in each study arm 
Study Study arms 
1 2 3 or more 
Standl et al, 2001 
[9] 
 
Metformin At least one 500-850 mg per tablet daily 
Glibenclamide 2-4 tablets (3.5 or 5 mg per tablet) 
Miglitol 25 mg tid for 4 weeks, 50 mg tid for 4 weeks, then 
50 or 100 mg tid 
Metformin At least one 500-850 mg per tablet daily 
Glibenclamide 2-4 tablets (3.5 or 5 mg per tablet) 
Placebo 
 
Yale et al, 2001 
[10] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Troglitazone 400 mg/day 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Placebo 
 
Heine et al, 2005 
[11] 
 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Insulin glargine 10 U/d then titrated to achieve  
FBG<5.6 mmol/L on daily glucose monitoring 
 
Kendall et al, 2005 
[12] 
Metformin Prestudy level 
Sulfonylurea Randomized to either maximally effective or 
minimum recommended dose 
Exenatide 10 µg bid 
Metformin Prestudy level 
Sulfonylurea Randomized to either maximally 
effective or minimum recommended dose 
Placebo 
(Not included) 
As for arm 1 with 
Exenatide in 5 µg dosage 
 
Roberts et al, 2005 
[13] 
 
Metformin Prestudy level 
Thiazolidinedione Prestudy level 
Glimepiride 2 mg/day 
Metformin Prestudy level 
Thiazolidinedione Prestudy level 
Placebo 
 
Rosenstock et al, 
2006 [14] 
Metformin 2000 mg/day 
Sulfonylurea Prestudy level 
Rosiglitazone 4 mg/day for 6 weeks, then 4-8 mg/day 
Metformin 2000 mg/day 
Sulfonylurea Prestudy level 
Insulin glargine 10 IU/day for 7 days, then titrated to 
achieve FPG <5.5-6.7 mmol/L 
 
Hermansen et al, 
2007 [15] 
Metformin 1500-3000 mg/day 
Glimepiride 4-8 mg/day 
Sitagliptin 100 mg qd 
Metformin 1500-3000 mg/day 
Glimepiride 4-8 mg/day 
Placebo 
 
Nauck et al, 2007 
[16] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Premixed insulin bid 
 
Kadoglou et al, 
2008 [17] 
Metformin Prestudy level 
Gliclazide Prestudy level 
Rosiglitazone 8 mg/day 
Metformin Prestudy level 
Gliclazide Prestudy level 
 
 
Bergenstal et al, Metformin Prestudy level Metformin Prestudy level Metformin Prestudy level 
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2009 [18] Sulfonylurea Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Sulfonylurea Prestudy level 
Biphasic insulin 12 U qd 
Biphasic insulin 6 U bid 
Juurinen et al, 
2009 [19] 
Metformin 500 mg/day 
Basal insulin Titrated to achieve FPG 4-5.5 mmol/L 
Nateglinide 120 mg tid 
Metformin 500 mg/day 
Basal insulin Titrated to achieve FPG 4-5.5 mmol/L 
Placebo 
 
Raskin et al, 2009 
[20] 
Metformin 2500 mg/day 
Pioglitazone 30 or 45 mg/day 
BIAsp 30 6 units bid titrated every 3-4 days to achieve FPG 
and pre-evening meal PG 4.4-6.1 mmol/L 
Metformin 2500 mg/day 
Pioglitazone 30 or 45 mg/day 
 
 
Russell-Jones et al, 
2009 [21]  
Metformin 2000 mg/day 
Glimepiride 4 mg/day 
Liraglutide 0.6 mg qd with weekly increments of 0.6 mg 
reaching final daily dose of 1.8 mg 
Metformin 2000 mg/day 
Glimepiride 4 mg/day 
Insulin glargine Titrated twice weekly to achieve 
FPG≤5.5 mmol/L 
Metformin 2 g/day 
Glimepiride 4 mg/day 
Placebo 
Zinman et al, 2009 
[22] 
Metformin 1000 mg bid 
Rosiglitazone 4 mg bid 
Liraglutide 1.8 mg qd 
Metformin 1000 mg bid 
Rosiglitazone 4 mg bid 
Placebo 
(Not included) 
As for arm 1 with Liraglutide in 
1.2 mg dosage 
DeFronzo et al, 
2010 [23] 
Metformin Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Rosiglitazone 2 mg bid 4 weeks, then 4 mg bid 
Metformin Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Metformin Prestudy level 
Rosiglitazone 2 mg bid 4 
weeks, then 4 mg bid 
Liutkus et al, 2010 
[24] 
 
Metformin Prestudy level 
Thiazolidinedione Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Metformin Prestudy level 
Thiazolidinedione Prestudy level 
Placebo 
 
Vilsboll et al, 2010 
[25] 
Metformin Prestudy level 
Insulin Prestudy level 
Sitagliptin 100 mg qd 
Metformin Prestudy level 
Insulin Prestudy level 
Placebo 
 
Bosi et al, 2011 
[26] 
Metformin ≥1500 mg/day 
Pioglitazone 30 mg/day 
Alogliptin 25 mg/day 
Metformin ≥1500 mg/day 
Pioglitazone 45 mg/day 
Placebo 
 
Hollander et al, 
2011 [3] 
Metformin Prestudy level 
Sitagliptin 100 mg/day 
Insulin detemir Titrated weekly to achieve pre-breakfast PG 
4.0-6.0 mmol/L 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Sitagliptin 100 mg/day 
 
Owens et al, 2011 
[27] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Linagliptin 5 mg qd 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Placebo 
 
Barnett et al, 2012 Metformin Prestudy level Metformin Prestudy level  
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[28] Insulin Prestudy level 
Saxagliptin 5 mg/day 
Insulin Prestudy level 
Placebo 
DeFronzo et al, 
2012 [29] 
Metformin ≤1500 mg/day 
Pioglitazone 15, 30 or 45 mg/day 
Alogliptin 12.5 or 25 mg/day 
Metformin ≤1500 mg/day 
Pioglitazone 15, 30 or 45 mg/day 
 
(Not included) 
Arm 3 Metformin + Alogliptin 
Arm 4 Metformin + placebo 
DeVries et al, 2012 
[30] 
Metformin Prestudy level 
Liraglutide 1.8 mg/day 
Insulin detemir 10 U titrated weekly to achieve FPG 4.1-6.0 
mmol/L 
Metformin Prestudy level 
Liraglutide 1.8 mg/day 
 
 
Violante et al, 2012 
[31] 
Metformin Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Sitagliptin 100 mg qd 
Metformin Prestudy level 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Placebo 
 
Derosa et al, 2013 
[32] 
 
Metformin 2200 mg/day 
Pioglitazone 30 mg/day 
Sitagliptin 100 mg/day 
Metformin 2200 mg/day 
Pioglitazone 30 mg/day 
Glibenclamide 5 mg tid 
 
Dobs et al, 2013 
[33] 
 
Metformin 1500-2550 mg/day 
Rosiglitazone 4-8 mg/day 
Sitagliptin 100 mg/day 
Metformin 1500-2550 mg/day 
Rosiglitazone 4-8 mg/day 
Placebo 
 
Fonseca et al, 2013 
[34] 
Metformin 1500-2550 mg/day 
Pioglitazone 30-45 mg/day 
Sitagliptin 100 mg/day 
Metformin 1500-2550 mg/day 
Pioglitazone 30-45 mg/day 
Placebo 
 
Haring et al, 2013 
[35] 
Metformin ≥1500 mg/day 
Sulfonylurea Maximum recommended or tolerated dose 
Empagliflozin 25 mg/day 
Metformin ≥1500 mg/day 




As for arm 1 with Empagliflozin 
in 10 mg dosage 
Kothny et al, 2013 
[36] 
Metformin ≥1500 mg 
Insulin ≤1 U/kg/day 
Vildagliptin 50 mg bid 
Metformin ≥1500 mg 
Insulin ≤1 U/kg/day 
Placebo 
 
Liu et al, 2013 [37] Metformin Prestudy level 
Sulfonylurea Prestudy level 
Pioglitazone 30 mg/day 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Sitagliptin 100 mg/day 
 
Schernthaner et al, 
2013 [38] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Canagliflozin 300 mg qd 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Sitagliptin 100 mg qd 
 
Wilding et al, 2013 
[39] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
(Not included) 
As for arm 1 with canagliflozin 
S39 
 
 Canagliflozin 300 mg/day Placebo in 100 mg dosage 
Yki-Jarvinen et al, 
2013 [40] 
 
Metformin Prestudy level 
Basal insulin Prestudy level 
Linagliptin 5 mg/day 
Metformin Prestudy level 
Basal insulin Prestudy level 
Placebo 
 
Jabbour et al, 2014 
[41] 
Metformin ≥1500 mg/day 
Sitagliptin 100 mg/day 
Dapagliflozin 10 mg 
Metformin ≥1500 mg/day 
Sitagliptin 100 mg/day 
Placebo 
 
Kovacs et al, 2014 
[42] 
Metformin Prestudy level 
Pioglitazone Prestudy level 
Empagliflozin 25 mg qd 
Metformin Prestudy level 
Pioglitazone Prestudy level 
Placebo 
(Not included)  
As for arm 1 with empagliflozin 
in 10 mg dosage 
Lukashevich et al, 
2014 [43] 
Metformin ≥1500 mg/day 
Glimepiride ≥4 mg/day 
Vildagliptin 50 mg bid 
Metformin ≥1500 mg/day 
Glimepiride ≥4 mg/day 
Placebo 
 
Moses et al, 2014 
[44] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Saxagliptin 5 mg qd 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Placebo 
 
Wysham et al, 
2014 [45] 
Metformin 1500-3000 mg/day 
Pioglitazone 30-45 mg/day 
Exenatide 5 µg bid for 4 weeks, then 10 µg bid 
Metformin 1500-3000 mg/day 
Pioglitazone 30-45 mg/day 
Placebo Once weekly 
(Not included) 
Arm 3 as for arm 2 replacing 
placebo with dulaglutide 1.5 
mg once weekly 
Arm 4 as for arm 3 with 
dulaglutide in 0.75 mg dosage 
Home et al, 2015 
[46] 
Metformin Prestudy level 
Glimepiride 4 mg/day 
Albiglutide 30 mg/week 
Metformin Prestudy level 
Glimepiride 4 mg/day 
Pioglitazone 30 mg/day 
Metformin Prestudy level 
Glimepiride 4 mg/day 
Placebo 
Matthaei et al, 
2015 [47] 
Metformin Prestudy level 
Sulfonylurea Prestudy level 
Dapagliflozin 10 mg qd 
Metformin Prestudy level 









Supplementary table 2: Quality of included studies 
Study Jadad Scale [5] 
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Standl et al, 2001 [9] 1 0 N/A 1 1 0 1 4 Good 
Yale et al, 2001 [10] 1 1 0 1 1 0 1 5 Good 
Heine et al, 2005 [11] 1 1 0 0 0 N/A 1 3 Good 
Kendall et al, 2005 [12] 1 0 N/A 1 1 0 1 4 Good 
Roberts et al, 2005 [13] 1 1 -1 1 1 0 1 4 Good 
Rosenstock et al, 2006 [14] 1 0 N/A 0 0 N/A 1 2 Poor 
Hermansen et al, 2007 [15] 1 1 0 1 1 0 1 5 Good 
Nauck et al, 2007 [16] 1 1 0 0 0 N/A 1 3 Good 
Kadoglou et al, 2008 [17] 1 0 N/A 0 0 N/A 1 2 Poor 
Bergenstal et al, 2009 [18] 1 1 0 0 0 N/A 1 3 Good 
Juurinen et al, 2009 [19] 1 1 0 1 1 0 1 5 Good 
Raskin et al, 2009 [20] 1 0 N/A 0 0 N/A 1 2 Poor 
Russell-Jones et al, 2009 [21] 1 1 0 1 1 -1 1 4 Good 
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Zinman et al, 2009 [22] 1 1 0 1 1 0 1 5 Good 
DeFronzo et al, 2010 [23] 1 1 0 0 0 N/A 1 3 Good 
Liutkus et al, 2010 [24] 1 1 -1 1 1 0 1 4 Good 
Vilsboll et al, 2010 [25] 1 1 0 1 1 0 1 5 Good 
Bosi et al, 2011 [26] 1 0 N/A 1 1 0 1 4 Good 
Hollander et al, 2011 [3] 1 1 0 0 0 N/A 1 3 Good 
Owens et al, 2011 [27] 1 0 N/A 1 1 0 1 4 Good 
Barnett et al, 2012 [28] 1 1 0 1 1 0 1 5 Good 
DeFronzo et al, 2012[29] 1 0 N/A 1 1 0 1 4 Good 
DeVries et al, 2012 [30] 1 1 0 0 0 N/A 1 3 Good 
Violante et al, 2012 [31] 1 0 N/A 1 1 0 1 4 Good 
Derosa et al, 2013 [32] 1 1 0 1 1 0 1 5 Good 
Dobs et al, 2013 [33] 1 1 0 1 1 0 1 5 Good 
Fonseca et al, 2013 [34] 1 0 N/A 1 1 0 1 4 Good 
Haring et al, 2013 [35] 1 1 0 1 1 0 1 5 Good 
Kothny et al, 2013 [36] 1 1 0 1 1 0 1 5 Good 
Liu et al, 2013 [37] 1 1 0 0 0 N/A 1 3 Good 
Schernthaner et al, 2013 [38] 1 1 0 1 1 0 1 5 Good 
Wilding et al, 2013 [39] 1 1 0 1 1 0 1 5 Good 
Yki-Jarvinen et al, 2013 [40] 1 1 0 1 1 0 1 5 Good 
Jabbour et al, 2014 [41] 1 0 N/A 1 1 0 1 4 Good 
Kovacs et al, 2014 [42] 1 1 0 1 1 0 1 5 Good 
Lukashevich et al, 2014 [43] 1 0 N/A 1 1 0 1 4 Good 
Moses et al, 2014 [44] 1 1 -1 1 1 0 1 4 Good 
Wysham et al, 2014 [45] 1 1 0 0 1 -1 1 3 Good 
Home et al, 2015 [46] 1 1 0 1 1 0 1 5 Good 








Supplementary table 3: Estimated mean difference (95% confidence intervals) in HbA1c* (%) for all pairwise therapy combinations obtained from 
consistency model 
 Third therapy added None/placebo SU DPP-4 GLP-1 SGLT2 
None/placebo None/placebo -0.59 (-0.90,-0.28) -0.56 (-0.71,-0.42) -0.81 (-1.01,-0.62) -0.69 (-0.92,-0.46) 
SU 0.59 (0.28,0.90) SU 0.03 (-0.29,0.35) -0.23 (-0.57,0.12) -0.10 (-0.48,0.28) 
DPP-4 0.56 (0.42,0.71) -0.03 (-0.35,0.29) DPP-4 -0.25 (-0.49,-0.01) -0.13 (-0.39,0.13) 
GLP-1 0.81 (0.62,1.01) 0.23 (-0.12,0.57) 0.25 (0.01,0.49) GLP-1 0.12 (-0.18,0.43) 
SGLT2 0.69 (0.46,0.92) 0.10 (-0.28,0.48) 0.13 (-0.13,0.39) -0.12 (-0.43,0.18) SGLT2 
INS 0.91 (0.68,1.13) 0.32 (-0.03,0.66) 0.35 (0.08,0.61) 0.09 (-0.14,0.32) 0.22 (-0.11,0.54) 
AGI 0.35 (-0.29,0.99) -0.24 (-0.95,0.47) -0.21 (-0.87,0.45) -0.46 (-1.14,0.21) -0.34 (-1.02,0.34) 
TZD 0.94 (0.69,1.18) 0.35 (-0.03,0.73) 0.38 (0.10,0.65) 0.12 (-0.16,0.41) 0.25 (-0.09,0.58) 
MEG 0.37 (-0.26,1.00) -0.22 (-0.92,0.48) -0.19 (-0.84,0.45) -0.44 (-1.10,0.21) -0.32 (-0.99,0.35) 
 
 Third therapy added INS AGI TZD MEG 
None/placebo -0.91 (-1.13,-0.68) -0.35 (-0.99,0.29) -0.94 (-1.18,-0.69) -0.37 (-1.00,0.26) 
SU -0.32 (-0.66,0.03) 0.24 (-0.47,0.95) -0.35 (-0.73,0.03) 0.22 (-0.48,0.92) 
DPP-4 -0.35 (-0.61,-0.08) 0.21 (-0.45,0.87) -0.38 (-0.65,-0.10) 0.19 (-0.45,0.84) 
GLP-1 -0.09 (-0.32,0.14) 0.46 (-0.21,1.14) -0.12 (-0.41,0.16) 0.44 (-0.21,1.10) 
SGLT2 -0.22 (-0.54,0.11) 0.34 (-0.34,1.02) -0.25 (-0.58,0.09) 0.32 (-0.35,0.99) 
INS INS 0.56 (-0.12,1.24) -0.03 (-0.33,0.27) 0.54 (-0.13,1.21) 
AGI -0.56 (-1.24,0.12) AGI -0.59 (-1.28,0.10) -0.02 (-0.92,0.88) 
TZD 0.03 (-0.27,0.33) 0.59 (-0.10,1.28) TZD 0.57 (-0.11,1.24) 
MEG -0.54 (-1.21,0.13) 0.02 (-0.88,0.92) -0.57 (-1.24,0.11) MEG 
*Multiply HbA1c values by 11 to convert HbA1c in DCCT (%) to IFCC (mmol/mol) 
AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-
glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione; 
 
A positive value suggests that the reduction in HbA1c is worse with the column therapy combination in comparison to the row therapy combination. 




Supplementary table 4: Estimated mean difference (95% confidence intervals) in body weight (kg) for all pairwise therapy combinations obtained from 
consistency model 
 
Third therapy added None/placebo SU DPP-4 GLP-1 SGLT2 
None/placebo None/placebo 3.23 (1.56,4.90) 0.02 (-0.87,0.92) -1.85 (-2.81,-0.89) -1.79 (-3.03,-0.55) 
SU -3.23 (-4.90,-1.56) SU -3.21 (-4.94,-1.48) -5.08 (-7.00,-3.16) -5.02 (-7.10,-2.94) 
DPP-4 -0.02 (-0.92,0.87) 3.21 (1.48,4.94) DPP-4 -1.88 (-3.17,-0.58) -1.81 (-3.34,-0.29) 
GLP-1 1.85 (0.89,2.81) 5.08 (3.16,7.00) 1.88 (0.58,3.17) GLP-1 0.06 (-1.50,1.63) 
SGLT2 1.79 (0.55,3.03) 5.02 (2.94,7.10) 1.81 (0.29,3.34) -0.06 (-1.63,1.50) SGLT2 
INS -2.34 (-3.51,-1.18) 0.89 (-1.14,2.92) -2.32 (-3.77,-0.87) -4.19 (-5.32,-3.07) -4.13 (-5.83,-2.43) 
TZD -2.72 (-3.99,-1.45) 0.51 (-1.56,2.58) -2.70 (-4.15,-1.25) -4.57 (-6.02,-3.13) -4.51 (-6.29,-2.74) 
MEG -0.20 (-3.14,2.74) 3.03 (-0.35,6.41) -0.18 (-3.25,2.90) -2.05 (-5.14,1.04) -1.99 (-5.18,1.20) 
 
Third therapy added INS TZD MEG 
None/placebo 2.34 (1.18,3.51) 2.72 (1.45,3.99) 0.20 (-2.74,3.14) 
SU -0.89 (-2.92,1.14) -0.51 (-2.58,1.56) -3.03 (-6.41,0.35) 
DPP-4 2.32 (0.87,3.77) 2.70 (1.25,4.15) 0.18 (-2.90,3.25) 
GLP-1 4.19 (3.07,5.32) 4.57 (3.13,6.02) 2.05 (-1.04,5.14) 
SGLT2 4.13 (2.43,5.83) 4.51 (2.74,6.29) 1.99 (-1.20,5.18) 
INS INS 0.38 (-1.15,1.91) -2.14 (-5.31,1.02) 
TZD -0.38 (-1.91,1.15) TZD -2.52 (-5.73,0.68) 
MEG 2.14 (-1.02,5.31) 2.52 (-0.68,5.73) MEG 
AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-
glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione; 
 
A positive value indicates that the body weight outcome is worse with the column therapy combination in comparison to the row therapy combination. 





Supplementary table 5: Estimated odds ratios (95% confidence intervals) of hypoglycaemia for all pairwise therapy combinations obtained from consistency 
mode 
 
 Third therapy added None/placebo SU DPP-4 GLP-1 SGLT2 
None/placebo None/placebo 2.59 (0.90,7.45) 1.95 (1.15,3.29) 2.61 (1.42,4.79) 2.27 (1.07,4.82) 
SU 0.39 (0.13,1.11) SU 0.75 (0.23,2.44) 1.01 (0.30,3.41) 0.88 (0.24,3.21) 
DPP-4 0.51 (0.30,0.87) 1.33 (0.41,4.30) DPP-4 1.34 (0.61,2.94) 1.17 (0.51,2.65) 
GLP-1 0.38 (0.21,0.71) 0.99 (0.29,3.36) 0.75 (0.34,1.64) GLP-1 0.87 (0.33,2.28) 
SGLT2 0.44 (0.21,0.93) 1.14 (0.31,4.16) 0.86 (0.38,1.95) 1.15 (0.44,3.01) SGLT2 
INS 0.17 (0.08,0.36) 0.44 (0.12,1.58) 0.33 (0.13,0.80) 0.44 (0.20,0.94) 0.38 (0.13,1.10) 
AGI 0.96 (0.02,60.55) 2.47 (0.03,178.76) 1.86 (0.03,121.88) 2.49 (0.04,164.93) 2.17 (0.03,147.07) 
TZD 0.35 (0.15,0.82) 0.91 (0.24,3.55) 0.69 (0.27,1.76) 0.92 (0.38,2.26) 0.80 (0.26,2.45) 
MEG 0.45 (0.09,2.33) 1.17 (0.17,8.22) 0.88 (0.16,4.92) 1.18 (0.21,6.76) 1.03 (0.17,6.23) 
 
 Third therapy added INS AGI TZD MEG 
None/placebo 5.94 (2.80,12.60) 1.05 (0.02,66.23) 2.83 (1.22,6.57) 2.20 (0.43,11.30) 
SU 2.30 (0.63,8.35) 0.40 (0.01,29.26) 1.09 (0.28,4.25) 0.85 (0.12,5.98) 
DPP-4 3.05 (1.25,7.44) 0.54 (0.01,35.14) 1.45 (0.57,3.70) 1.13 (0.20,6.30) 
GLP-1 2.28 (1.06,4.89) 0.40 (0.01,26.58) 1.09 (0.44,2.67) 0.85 (0.15,4.84) 
SGLT2 2.61 (0.91,7.52) 0.46 (0.01,31.21) 1.25 (0.41,3.80) 0.97 (0.16,5.87) 
INS INS 0.18 (0.00,11.94) 0.48 (0.19,1.21) 0.37 (0.06,2.25) 
AGI 5.68 (0.08,384.58) AGI 2.70 (0.04,186.44) 2.11 (0.02,182.08) 
TZD 2.10 (0.83,5.32) 0.37 (0.01,25.49) TZD 0.78 (0.12,4.90) 
MEG 2.69 (0.45,16.28) 0.47 (0.01,40.98) 1.28 (0.20,8.07) MEG 
AGI=alpha glucosidase inhibitor; DPP-4=dipeptidyl peptidase 4 inhibitor; GLP-1=Glucagon-like peptide-1 receptor agonist; INS=insulin; SGLT2=sodium-
glucose linked transporter protein 2 inhibitor; SU=sulfonylurea; TZD= thiazolidinedione; 
 
A value greater than one indicates that the column therapy combination is associated with greater odds of hypoglycaemia than the row therapy 





Supplementary figure 1: Flow diagram for identifying eligible studies 
 
 
 
